🇺🇸 GH — Guardant Health, Inc.

Salud Compra fuerte
← Volver

Precio actual

175,00 USD

Máx. histórico

187,22

29 días

Caída desde máximo

-6,53%

Rango 52 semanas

74,55 – 191,05

Variación hoy

+2,50%

Cierre anterior

170,73

Rango de hoy

167,31 – 178,38

Volumen hoy

1.720.775

Peor caída histórica

-91,03%

12/02/2021 → 19/04/2024

Recuperado en 881 días

Volatilidad anualizada ⓘ

67,35%

Información
Nombre completo
Guardant Health, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Diagnostics & Research
Empleados
2.490
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
202,24 USD (puede no estar actualizado)
Primera cotización
04/10/2018
Precio actualizado
hace 17 horas
Sobre la empresa

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/03/2022 58,18 58,93 53,50 53,68 -7,32% 9,33% 1.497.200
04/03/2022 60,32 62,52 57,14 57,92 -4,50% 8,92% 874.100
03/03/2022 66,39 66,39 60,36 60,65 -7,73% 9,08% 1.079.700
02/03/2022 66,04 66,65 63,14 65,73 -0,90% 5,31% 848.500
01/03/2022 66,52 69,05 65,61 66,33 +0,09% 5,17% 776.400
28/02/2022 65,68 68,63 65,26 66,27 +0,09% 5,13% 922.500
25/02/2022 65,54 66,74 63,37 66,21 +0,93% 5,14% 1.030.700
24/02/2022 58,77 65,81 56,81 65,60 +10,01% 15,31% 1.804.900
23/02/2022 63,15 63,39 59,13 59,63 -3,68% 6,75% 1.350.500
22/02/2022 61,28 63,58 60,66 61,91 -0,31% 4,77% 1.567.500
18/02/2022 64,63 64,86 60,84 62,10 -4,15% 6,22% 1.021.500
17/02/2022 69,19 69,19 64,40 64,79 -7,77% 6,92% 905.500
16/02/2022 71,38 72,05 68,03 70,25 -2,94% 5,63% 730.400
15/02/2022 71,50 73,44 71,31 72,38 +3,40% 2,98% 785.300
14/02/2022 71,74 73,72 69,73 70,00 -1,84% 5,56% 902.900
11/02/2022 73,79 75,40 70,08 71,31 -3,22% 7,21% 1.142.800
10/02/2022 73,80 78,34 72,64 73,68 -2,03% 7,72% 895.000
09/02/2022 73,49 76,86 73,31 75,21 +3,98% 4,83% 768.500
08/02/2022 71,84 74,02 71,31 72,33 -0,41% 3,77% 593.500
07/02/2022 72,03 76,68 72,00 72,63 -0,51% 6,50% 634.800
04/02/2022 71,06 73,62 70,35 73,00 +2,69% 4,60% 806.000
03/02/2022 68,91 71,83 68,49 71,09 +0,84% 4,85% 1.605.600
02/02/2022 72,42 73,39 68,44 70,50 -3,37% 6,84% 995.200
01/02/2022 70,49 73,24 67,70 72,96 +4,90% 7,86% 1.196.000
31/01/2022 63,23 69,82 63,00 69,55 +10,84% 10,79% 1.888.200
28/01/2022 61,33 63,55 59,57 62,75 +1,88% 6,49% 1.978.500
27/01/2022 65,01 66,41 61,17 61,59 -4,23% 8,06% 1.567.400
26/01/2022 68,06 69,58 63,45 64,31 -2,19% 9,01% 2.174.500
25/01/2022 69,81 71,27 65,07 65,75 -7,87% 8,88% 1.629.000
24/01/2022 68,94 71,86 65,21 71,37 +1,81% 9,65% 1.708.600